More News! For those who want to keep up with everything

Home More News! Page 17

Latest Posts

Mellissa Fisher microbial me

More News! 6 Jan 2018

A Self-Portrait of the Microbes that Live on our Skin

Is a portrait fully complete without portraying the millions of bacteria that live on our skin? Mellissa Fisher makes them the focus of her self-portraits. British artist Mellissa Fisher creates quite unique portraits. The material for her face sculptures is agar rich in nutrients, the same one that scientists use to grow bacteria and fungi […]

January 6, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

multiple sclerosis therapy rewind 1

More News! 4 Jan 2018

Belgian Biotech Hits ‘Fast Forward’ on Multiple Sclerosis Therapies

Rewind Therapeutics has received a boost in the development of its multiple sclerosis therapies, raising a €15.2M Series A fundraising round. Rewind Therapeutics is a young Belgian biotech, which was co-founded by CD3 and Axxam, based in Leuven, Belgium, and Milan, Italy, respectively. Today, the biotech announced that it has completed a €15.2M Series A financing […]

January 4, 2018 - 2 minutesmins - By Alex Dale

summit therapeutics new antibiotic

More News! 21 Dec 2017

Oxford Biotech Makes a Latin American Deal for Its Antibiotic

In a deal worth up to €23.6M, Summit Therapeutics licensed the commercialization of its new antibiotic ridinilazole to Eurofarma. Oxford-based Summit Therapeutics is working on new antibiotics to fight antimicrobial resistance. Its candidate ridinilazole has attracted the attention of a Brazilian pharma, Eurofarma, and the pair has made a deal for $2.5M (€2.1M) upfront and […]

December 21, 2017 - 1 minutemin - By Evelyn Warner

uk biotech life science strategy

More News! 21 Dec 2017

Britain’s Life Science Strategy: What UK Biotech Can Do From the Bottom Up

Britain has been making a concerted effort to grow its biotech sector, especially after Brexit. What’s the plan and what can UK biotech do? The last time I walked the the echoey corridors of the Palace of Westminster (UK parliament), I was a wee twelve-year old, on a mission to push forward legislation to prevent […]

December 21, 2017 - 6 minutesmins - By External Contributor

sensorion cochlear hearing loss

More News! 18 Dec 2017

French Biotech will work with the World’s Leader in Hearing Implants

Sensorion and Cochlear will explore if a combination of a drug and a hearing implant can improve the treatment of hearing loss. Based in the French city of Montpellier, Sensorion specializes in the development of treatments for inner ear disorders such as vertigo and hearing loss. The company’s technology received major recognition today with the […]

December 18, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

izana bioscience

More News! 14 Dec 2017

New Biotech in Oxford Takes on Arthritis of the Spine

Izana Bioscience has been launched today to develop an antibody to treat ankylosing spondylitis, a form of arthritis that affects the spine. Oxford’s newest biotech, Izana Bioscience, has an exclusive license from Takeda to develop the antibody drug Namilumab (IZN-101) and a £1.35M grant from Innovate UK to fund a Phase II study. The company plans to […]

December 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

ADVERTISEMENT

chemomab nash antibody peter thiel

More News! 5 Dec 2017

PayPal Co-Founder Backs Israeli Biotech Attacking NASH with an Antibody

ChemomAb kicked off its antibody efforts as a company in 2011, and its $10M Series B has attracted none other than Peter Thiel. Israeli biotech has been attracting quite sizeable funds recently, largely those of UK investment outfit Arix Bioscience. Yesterday it was announced that Peter Theil, co-founder of PayPal and assassin of Gawker, led […]

December 5, 2017 - 2 minutesmins - By Evelyn Warner

Kunstformen der Natur Ernst Haeckel

More News! 2 Dec 2017

Kunstformen der Natur: 19th Century Biology Art in Exhibition

Kunstformen der Natur, by Ernst Haeckel, is a beautiful series of prints that have influenced scientists and artists alike. A Dutch exhibition shows them like never before. In the fashion of the 19th century, Ernst Haeckel was simultaneously a biologist, philosopher, physician, and artist. A Darwin contemporary, although Haeckel supported Lamarckist and other evolutionary theories that are […]

December 2, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

antibiotic antibody staphylococcus symphogen 1

More News! 30 Nov 2017

Cha-Ching! Danish Biotech Gets $5M as Antibody-Antibiotic Combo Enters Phase Ib

A Phase Ib trial will assess the capacity of Symphogen’s antibody to direct an antibiotic to Staphylococcus infections for their effective treatment. Symphogen focuses on the development of antibodies for the treatment of cancer, but will receive a $5M (€4.2M) milestone payment from Genentech for the use of one of its antibodies against Staphylococcus aureus infections. It […]

November 30, 2017 - 2 minutesmins - By Alex Dale

Ken Rinaldo Borderless bacteria

More News! 18 Nov 2017

Bacterial Art Starts a Debate on Money and International Borders

We have been told over and over that bacteria are everywhere around us, especially on your smartphone screen. But most of us haven’t stopped to reflect on the fact — and consequences — of bacteria being all over our money. A scientific study by the New York University called the Dirty Money Project revealed in […]

November 18, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

neurimmune ono pharmaceutical neurodegenerative disease

More News! 9 Nov 2017

Swiss Biotech and Japanese Pharma Team Up to Tackle Neurodegenerative Disease

Neurimmune and Ono Pharmaceutical have partnered to develop an antibody drug against a still undisclosed neurodegenerative disease. Neurimmune has a new partner to help it develop treatments for neurodegenerative diseases. Ono Pharmaceutical will work together with the Swiss biotech to develop human antibodies against a new disease target that remains undisclosed for now. In exchange for an […]

November 9, 2017 - 1 minutemin - By Clara Rodríguez Fernández

multiple sclerosis treatment geneuro

More News! 1 Nov 2017

Swiss Biotech & French Pharma Reverse Damage in Multiple Sclerosis

A candidate multiple sclerosis treatment from GeNeuro and its partner Servier showed some remyelination in a post hoc analysis of Phase IIb data. GeNeuro’s stock rose by 30% on Monday following an announcement of promising results from its relapsing-remitting multiple sclerosis drug, GNbAC1. After six months, the highest dose demonstrated an anti-inflammatory effect and seemed to stimulate […]

November 1, 2017 - 2 minutesmins - By Evelyn Warner

ADVERTISEMENT